N,N'-diisopropyl-fumaramide | 116435-24-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N,N'-diisopropyl-fumaramide
• 英文别名: N,N'-Diisopropyl-fumaramid；Fumarsaeure-bis-isopropylamid；(E)-N,N'-diisopropylbut-2-enediamide；(E)-N,N'-di(propan-2-yl)but-2-enediamide
• CAS: 116435-24-6
• 化学式: C₁₀H₁₈N₂O₂
• 分子量: 198.265
• InChiKey: KBABPEPBRCQOGG-AATRIKPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N'-diisopropyl-fumaramide 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 1,4-Endoethylen-cyclohexan-trans-2,3-dicarbonsaeure-bis-isopropylamid
  参考文献：
  名称：

  Über alkylierte Amide bicyclischer Dicarbonsäuren, 4. Mitt.:

  摘要：

  DOI：

  10.1007/bf01185918
• 作为产物：
  描述：

  异丙醇 、 反丁烯二腈 在 硫酸 作用下， 生成 N,N'-diisopropyl-fumaramide
  参考文献：
  名称：

  A New Reaction of Nitriles. III. Amides from Dinitriles

  摘要：

  DOI：

  10.1021/ja01180a075

文献信息

• Osmium-Catalyzed Dihydroxylation of Olefins in Acidic Media: Old Process, New Tricks
  作者：Philippe Dupau、Robert Epple、Allen??A. Thomas、Valery??V. Fokin、K.??Barry Sharpless

  DOI：10.1002/1615-4169(200206)344:3/4<421::aid-adsc421>3.0.co;2-f

  日期：2002.6

  osmium-catalyzed dihydroxylation has uncovered that electron-deficient olefins are converted into the corresponding diols much more efficiently when the pH of the reaction medium is maintained on the acidic side. Further studies have identified citric acid as the additive of choice, for it allows preparation of very pure diols in yields generally exceeding 90%. As described here, a much wider range of olefin classes

  对锇催化的二羟基化中 500 多种不同功能化添加剂的筛选发现，当反应介质的 pH 值保持在酸性时，缺电子烯烃转化为相应二醇的效率更高。进一步的研究已将柠檬酸确定为首选添加剂，因为它可以制备非常纯的二醇，产率通常超过 90%。正如这里所描述的，现在可以成功地对更广泛的烯烃类别进行二羟基化。该过程在实验上很简单，在大多数情况下，只需将反应物溶解在水或水/叔丁醇混合物中，搅拌它们，然后过滤出纯二醇产物。
• Modifiable polyunsaturated polymers and processes for their preparation
  申请人：Parthiban Anbanandam

  公开号：US20060189774A1

  公开（公告）日：2006-08-24

  The present invention relates to modifiable linear polyunsaturated polymers and processes for preparing the same comprising reacting solely at least one bifunctional nucleophilic compound with at least one α-functional unsaturated monomer. The at least one bifunctional nucleophilic compound of the invention comprises two nucleophiles independently selected from the group consisting of C, N, O, S and Se. The at least one α-functional unsaturated monomer of the invention comprises two leaving groups L 1 and L 2 , wherein at least one of the leaving groups L 1 and L 2 of the at least one α-functional unsaturated monomer is part of the nonaromatic unsaturated structure C═C—C α -L. The double bond of said α-functional unsaturated monomer is maintained in the polyunsaturated polymer.

  本发明涉及可改性线性多不饱和聚合物以及制备该聚合物的工艺，包括仅使至少一种双官能团亲核化合物与至少一种α官能团不饱和单体反应。本发明的至少一种双官能团亲核化合物包括两个独立选自 C、N、O、S 和 Se 组的亲核物。本发明的至少一种 α-官能团不饱和单体包括两个离去基团 L 1 和 L 2 其中至少一个离去基团 L 1 和 L 2 的至少一个离去基团 L 1 和 L 2 是非芳香族不饱和结构 C═C-C α -L.所述 α-官能团不饱和单体的双键保留在多不饱和聚合物中。
• IAP bir domain binding compounds
  申请人：Boudreault Alain

  公开号：US20080069812A1

  公开（公告）日：2008-03-20

  Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R 1 , R 2 , R 3 , R 100 , R 200 , R 300 , A, A 1 , BG, Q and Q 1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.
• IAP BIR domain binding compounds
  申请人：Boudreault Alain

  公开号：US20080207525A1

  公开（公告）日：2008-08-28

  Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R 1 , R 2 , R 3 , R 100 , R 200 , R 300 , A, A 1 , BG, Q and Q 1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.
• IAP BIR DOMAIN BINDING COMPOUNDS
  申请人：Boudreault Alain

  公开号：US20100221261A1

  公开（公告）日：2010-09-02

  Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R 1 , R 2 , R 3 , R 100 , R 200 , R 300 , A, A 1 , BG, Q and Q 1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.